<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18745" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>C1 Esterase Inhibitor Deficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kerrigan</surname>
            <given-names>Matthew J.</given-names>
          </name>
          <aff>University of Nebraska Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Naik</surname>
            <given-names>Pratiksha</given-names>
          </name>
          <aff>Baylor scott and white memorial hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Matthew Kerrigan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Pratiksha Naik declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18745.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>C1 esterase inhibitor deficiency, also known as hereditary angioedema, results in the unchecked production of the vasodilator bradykinin. This increase in bradykinin leads to an increase in smooth muscle relaxation in the walls of blood vessels and resultant edema in the hands, feet, gastrointestinal tract, and in severe cases, the larynx. In severe cases, the airway can be compromised and effectively swollen closed, preventing air movement into and out of the lungs. This activity reviews the presentation, evaluation, and management of C1 esterase inhibitor deficiency, and highlights the role of the interprofessional team in caring for patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pertinent history and physical exam findings in a patient with C1 esterase inhibitor deficiency.</p></list-item><list-item><p>Review the presumptive versus the definitive diagnosis of C1 esterase inhibitor deficiency.</p></list-item><list-item><p>Summarize the management options available for C1 esterase inhibitor deficiency.</p></list-item><list-item><p>Explain how interprofessional teams can improve care coordination and communication to advance treatment for patients with C1 esterase inhibitor deficiency.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18745&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18745">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18745.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hereditary angioedema,&#x000a0;otherwise known as&#x000a0;C1 esterase deficiency, is defined by recurrent episodes of angioedema without urticaria or pruritus. These skin conditions typically involve the legs,&#x000a0;hands, face,&#x000a0;upper respiratory tract, as well as gastrointestinal tract. This disorder can lead to airway edema and potentially asphyxiation due to laryngeal swelling. Associated symptoms typically include abdominal pain and vomiting&#x000a0;secondary to gastrointestinal involvement.<xref ref-type="bibr" rid="article-18745.r1">[1]</xref></p>
      </sec>
      <sec id="article-18745.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Hereditary angioedema results from excessive production of bradykinin. Bradykinin is a vasodilator that causes the larynx to become engorged and swollen, threatening the airway. Due to this pathway, the swelling is not amenable to antihistamines as it is not a histamine-mediated process. While there are other forms of hereditary angioedema, deficiency or dysfunction in C1 inhibitor is the most common form. C1 inhibitor is an acute phase reactant and a serine protease inhibitor (serpin). Serpins inhibit the steps in the lectin complement pathway as well as kinin-producing pathways. While C1 inhibitor has many functions, its function in the kinin pathway leads to angioedema.<xref ref-type="bibr" rid="article-18745.r2">[2]</xref></p>
        <p>While it is uncertain what causes the initial molecular events leading to this angioedema, it is believed activated factor XII of the coagulation cascade and kallikrein catalyze the cleavage of kininogen, which produces bradykinin. C1 inhibitor usually limits this bradykinin production by inhibiting kallikrein and factor XIIa. Bradykinin&#x000a0;is a potent vasodilator&#x000a0;due&#x000a0;to multifactorial downstream effects on the smooth muscle in blood vessels. This activity, in turn, leads to edema of surrounding tissues and, most importantly,&#x000a0;the airway.&#x000a0;In individuals with a deficiency of C1 inhibitor, this process proceeds unchecked and leads to gross vasodilation and angioedema.<xref ref-type="bibr" rid="article-18745.r1">[1]</xref></p>
      </sec>
      <sec id="article-18745.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Hereditary angioedema has an incidence of approximately 1 in 50000 individuals. While there are nearly 300 pathogenic variants, most are inherited in an autosomal dominant fashion, with approximately 25% of cases arising from de novo mutations. This condition leads to about 15000 to 30000 emergency department visits per year.<xref ref-type="bibr" rid="article-18745.r1">[1]</xref></p>
      </sec>
      <sec id="article-18745.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The most clinically significant sequelae of C1 inhibitor deficiency is the potential for laryngeal edema and subsequent asphyxiation due to angioedema from unchecked bradykinin effects. The pathophysiology of C1 esterase inhibitor deficiency largely stems from the increased bradykinin production. Increased levels of bradykinin then lead to smooth muscle relaxation in the walls of blood vessels which causes edema. If severe enough, the airway can be compromised and effectively&#x000a0;swollen closed, preventing air movement into and&#x000a0;out of the lungs.<xref ref-type="bibr" rid="article-18745.r3">[3]</xref></p>
      </sec>
      <sec id="article-18745.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>When suspecting C1 esterase deficiency, key historical findings such as a family history for the disease or upper airway swelling may be noted. Additionally, a history of unexplained recurrent episodes of self-limited colicky abdominal pain may be present. History of angioedema without urticaria, pruritus, ACE inhibitor, NSAID, or allergic exposure is highly suggestive&#x000a0;as well. Common sites that are affected include the hands and feet&#x000a0;as well.<xref ref-type="bibr" rid="article-18745.r1">[1]</xref></p>
      </sec>
      <sec id="article-18745.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>When&#x000a0;suspecting C1 esterase inhibitor deficiency, it may present with airway compromise from laryngeal edema or a more benign presentation of unexplained&#x000a0;hands and foot swelling. First, care should be taken to ensure the airway is secured; this can be via traditional airway methods but will be made difficult due to airway swelling. Further evaluation should take place on a trial basis of classic allergic airway swelling management (epinephrine, steroids, antihistamines). In the case of C1 inhibitor deficiency, these methods will not work. At this point, a presumptive diagnosis can be made,&#x000a0;but for a definitive diagnosis, clinicians can obtain C4 levels. In the case of C1 inhibitor deficiency, C4 levels will be low. Further testing can include C1NH protein levels and function studies for definitive diagnosis.<xref ref-type="bibr" rid="article-18745.r4">[4]</xref></p>
      </sec>
      <sec id="article-18745.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management of C1 esterase inhibitor deficiency is mostly in response to airway compromise. If only mild symptoms present and the patient has a known diagnosis, it is reasonable to manage conservatively with observation. If more severe symptoms and impending airway compromise are present, a definitive airway is necessary. Presumptive treatment with epinephrine, steroids, and antihistamines is recommended&#x000a0;of the undifferentiated patient with airway compromise secondary to laryngeal edema. However, in the setting of C1 esterase inhibitor deficiency, this is ineffective but should be attempted as allergic airway compromise is more common, and these methods have a high reward with relatively little downside.<xref ref-type="bibr" rid="article-18745.r5">[5]</xref></p>
        <p>Specific therapy for C1 esterase inhibitor deficiency with laryngeal edema involves replacing the deficient enzyme. The easiest way is to give human plasma, which contains C1 esterase inhibitor. An initial dose of human plasma is 2 units.&#x000a0;C1INH concentrate derived&#x000a0;from human plasma may be a therapeutic option.&#x000a0;The initial dose is 1500 units.<xref ref-type="bibr" rid="article-18745.r6">[6]</xref></p>
        <p>More specific, less widely used medications include Icatibant and ecallantide. Icatibant&#x000a0;is a synthetic bradykinin B2-receptor antagonist, while ecallantide is a recombinant plasma kallikrein inhibitor.<xref ref-type="bibr" rid="article-18745.r5">[5]</xref><xref ref-type="bibr" rid="article-18745.r6">[6]</xref></p>
      </sec>
      <sec id="article-18745.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Differential diagnosis in the setting of airway edema includes:</p>
        <list list-type="bullet">
          <list-item>
            <p>Anaphylaxis/allergic</p>
          </list-item>
          <list-item>
            <p>ACE inhibitor-induced edema</p>
          </list-item>
          <list-item>
            <p>Idiopathic</p>
          </list-item>
          <list-item>
            <p>Autoimmune disorders</p>
          </list-item>
          <list-item>
            <p>Superior vena cava syndrome</p>
          </list-item>
          <list-item>
            <p>Thyroid disorders</p>
          </list-item>
          <list-item>
            <p>Cheilitis granulomatosa</p>
          </list-item>
          <list-item>
            <p>Trichinosis&#x000a0;</p>
          </list-item>
        </list>
        <p>The possible differentials can broaden when symptoms relate solely to extremity swelling:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Lymphedema</p>
          </list-item>
          <list-item>
            <p>Deep vein thrombosis</p>
          </list-item>
          <list-item>
            <p>Cellulitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18745.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Depending on the response to therapy, the patient should return to normal health. Occasionally patients are very&#x000a0;resistant to therapy and will require intubation. After the acute event and extubation, the patient should have a full recovery.&#x000a0;The chance of recurrence, however, is always present.<xref ref-type="bibr" rid="article-18745.r7">[7]</xref></p>
      </sec>
      <sec id="article-18745.s11" sec-type="Complications">
        <title>Complications</title>
        <p>The most severe complication is airway compromise requiring intubation or surgical airway; standard airway procedures and protocols should manage this situation.<xref ref-type="bibr" rid="article-18745.r6">[6]</xref></p>
      </sec>
      <sec id="article-18745.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>If attempts at the airway are unsuccessful, a surgical airway may be necessary. Consultation with the anesthesia team may be of some benefit if there is a possibility of a difficult airway.</p>
      </sec>
      <sec id="article-18745.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <list list-type="bullet">
          <list-item>
            <p>Avoid physical and psychological stressors.</p>
          </list-item>
          <list-item>
            <p>Medications to avoid include: estrogen, tamoxifen, and ACE inhibitors</p>
          </list-item>
          <list-item>
            <p>Patients who&#x000a0;are to undergo oral surgery should receive prophylaxis which includes attenuated androgens, regular C1INH infusions, and&#x000a0;tranexamic&#x000a0;acid infusion</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18745.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>When caring for a patient with hereditary angioedema, the ABCs of resuscitation should&#x000a0;be first and&#x000a0;foremost. Assigning team roles and frequently assessing the patient for airway compromise is paramount. Having the appropriate&#x000a0;tools for intubation, such as visual&#x000a0;laryngoscopes and backup airway devices, is part of the&#x000a0;key to success. Patients with even concern for airway compromise should be monitored closely in the intensive care setting.<xref ref-type="bibr" rid="article-18745.r6">[6]</xref></p>
      </sec>
      <sec id="article-18745.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18745&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18745">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/c1-esterase-inhibitor-deficiency/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=18745">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18745/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18745">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18745.s16">
        <title>References</title>
        <ref id="article-18745.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fragnan</surname>
                <given-names>NTML</given-names>
              </name>
              <name>
                <surname>Tolentino</surname>
                <given-names>ALN</given-names>
              </name>
              <name>
                <surname>Borba</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Oliveira</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Sim&#x000f5;es</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Palma</surname>
                <given-names>SMU</given-names>
              </name>
              <name>
                <surname>Constantino-Silva</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Grumach</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Hereditary angioedema with C1 inhibitor (C1-INH) deficit: the strength of recognition (51 cases).</article-title>
            <source>Braz J Med Biol Res</source>
            <year>2018</year>
            <month>Nov</month>
            <day>14</day>
            <volume>51</volume>
            <issue>12</issue>
            <fpage>e7813</fpage>
            <pub-id pub-id-type="pmid">30462774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bindke</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schorling</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wieczorek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kapp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wedi</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>[Gender aspects in angioedema].</article-title>
            <source>Hautarzt</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>92</fpage>
            <page-range>92-100</page-range>
            <pub-id pub-id-type="pmid">30627747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ivanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Matafonov</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Mohammed</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Dickeson</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Kundu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Verhamme</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Gruber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McCrae</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gailani</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.</article-title>
            <source>Blood</source>
            <year>2019</year>
            <month>Mar</month>
            <day>07</day>
            <volume>133</volume>
            <issue>10</issue>
            <fpage>1152</fpage>
            <page-range>1152-1163</page-range>
            <pub-id pub-id-type="pmid">30591525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehmood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abdullah</surname>
                <given-names>HMA</given-names>
              </name>
              <name>
                <surname>Inayat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Ullah</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Wolf in the sheep's clothing: intestinal angioedema mimicking infectious colitis.</article-title>
            <source>BMJ Case Rep</source>
            <year>2018</year>
            <month>Dec</month>
            <day>13</day>
            <volume>11</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">30567241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Riedl</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Cicardi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Longhurst</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Zuraw</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Busse</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Magerl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Martinez-Saguer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Davis-Lorton</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zanichelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Craig</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnston</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Lumry</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Shennak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Soteres</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zaragoza-Urdaz</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Gierer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Tachdjian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wedner</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hebert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rehman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Staubach</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schranz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baptista</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nothaft</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Maurer</surname>
                <given-names>M</given-names>
              </name>
              <collab>HELP Investigators</collab>
            </person-group>
            <article-title>Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>320</volume>
            <issue>20</issue>
            <fpage>2108</fpage>
            <page-range>2108-2121</page-range>
            <pub-id pub-id-type="pmid">30480729</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barmettler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>New and evolving therapies for hereditary angioedema.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2019</year>
            <month>Jan</month>
            <day>01</day>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-13</page-range>
            <pub-id pub-id-type="pmid">30582490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18745.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bean</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Keswani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kannan</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Hereditary angioedema and inducible urticaria: Not mutually exclusive.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>122</volume>
            <issue>4</issue>
            <fpage>430</fpage>
            <page-range>430-431</page-range>
            <pub-id pub-id-type="pmid">30605735</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
